Xeris Record Financial Results for Q2, Raises Full Year Revenue Guidance

 Total revenue increased 49% YoY to $71.5 million; Recorlev® revenue grew 136% YoY

Raises full-year 2025 total revenue guidance to $280-$290 million from previous range of $260-$275 million

Provided long-term outlook at Analyst and Investor Day in June

Hosts conference call and webcast today at 8:30 a.m. ET

Upcoming Events

• Cantor Fitzgerald Global Healthcare Conference: Senior management will participate in 1x1 meetings on September 3, 2025 in New York City, NY. Please contact the sponsor to arrange meetings with management.
• Wells Fargo Global Healthcare Conference: Senior management will participate in 1x1 meetings on September 4, 2025 in Boston, MA. Please contact the sponsor to arrange meetings with management.
• H.C. Wainwright Global Investment Conference: Senior management will participate in 1x1 meetings on September 9, 2025 in New York City, NY. Please contact the sponsor to arrange meetings with management.

Strategic Updates

• On June 3, 2025, the Company hosted its first-ever Analyst and Investor Day, providing a comprehensive overview of its strategic vision for sustainable growth and long-term value creation. During the event, management reiterated its confidence in the Company’s robust growth trajectory—both near- and long-term—driven by disciplined execution across its portfolio. Key highlights included updates on the Company's two core growth drivers: Recorlev® and XP-8121, its investigational subcutaneous levothyroxine candidate.

1 Adjusted EBITDA is a non-GAAP financial measure. See "Note Regarding Use of Non-GAAP Financial Measures" and the corresponding financial tables at the end of this press release for definitions and reconciliations of non-GAAP measures.

Conference Call and Webcast Details

Xeris will host a conference call and webcast at 8:30 a.m. Eastern Time today to discuss the Company's financial and operational results. To pre-register for the conference call, please use the following link: https://www.netroadshow.com/events/login/LE9zwo3gmwDLA5JeSSHtiUIAhliB0lMHV58

After registering, a confirmation email will be sent, including dial-in details and a unique code for entry. The Company recommends registering a minimum of ten minutes prior to the start of the call. Following the conference call, a replay will be available until Thursday, August 21, 2025 at US:1 929 458 6194, US Toll Free: 1 866 813 9403, UK: 0204 525 0658, Canada: 1 226 828 7578, or all other locations: +44 204 525 0658 Access Code: 520958.

To join the webcast, please visit “Events” on investor relations page of the Company’s website at www.xerispharma.com or use this link: https://events.q4inc.com/attendee/341157374

https://www.businesswire.com/news/home/20250807913489/en/Xeris-Biopharma-Reports-Record-Financial-Results-for-the-Second-Quarter-2025-and-Raises-Full-Year-Revenue-Guidance